FDA Accepts New Drug Application for Corcept Therapeutics’s (CORT) Relacorilant

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the Best Performing Long Term Stocks According to Analysts. On September 10, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced that the FDA has accepted its new drug application for Relacorilant to treat platinum-resistant ovarian cancer.

Management noted that the FDA has set a decision date of July 11, 2026, under the Prescription Drug User Fee Act. The application acceptance is based on the positive results from the Phase 3 ROSELLA trial and earlier Phase 2 studies.

In these trials, Relacorilant was combined with the chemotherapy drug nab-paclitaxel. The results showed that patients receiving this combination showed better progression-free survival and overall survival than those on nab-paclitaxel alone. Notably, Relacorilant did not add safety risks, while the rates and severity of side effects were similar between the combination and monotherapy groups.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company that discovers, develops, and commercializes medications targeting severe diseases by modulating cortisol, a hormone linked to various disorders.

While we acknowledge the potential of CORT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.